OncoMatch/Clinical Trials/NCT06663072
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
Is NCT06663072 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Fulvestrant and 177Lu-DOTATATE for metastatic pancreatic neuroendocrine tumor.
Treatment: Fulvestrant · 177Lu-DOTATATE — This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Disease stage
Grade: 12 (who)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
radiographically progressed (as per RECIST v1.1 criteria) on one or more prior-lines of systemic therapy prior to enrollment in the trial
Cannot have received: peptide receptor radionuclide therapy (177Lu-DOTATATE)
should not have received any prior systemic therapy with peptide receptor radionuclide therapy (including 177Lu-DOTATATE)
Cannot have received: estrogen receptor antagonist (Fulvestrant)
should not have received any prior systemic therapy with ... Fulvestrant
Lab requirements
Blood counts
absolute neutrophil count ≥1,500/µl; platelet count ≥100,000/µl; hemoglobin ≥ 9g/dl
Kidney function
creatinine <1.5 mg/dl or creatinine clearance ≥ 50 ml/min (cockroft-gault calculated)
Liver function
total bilirubin ≤ 1.5 × institutional upper limit of normal; ast and alt ≤ 3 × institutional upper limit of normal; serum albumin ≥ 3.0 g/dl
Cardiac function
nyha functional classification class 2b or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Chicago Medicine Comprehensive Cancer Center · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify